# Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

> **NCT07282054** · PHASE3 · COMPLETED · sponsor: **Tonghua Dongbao Pharmaceutical Co.,Ltd** · enrollment: 550 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** THDB0206
- **DRUG:** Insulin Lispro
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT07282054
- **Lead sponsor:** Tonghua Dongbao Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-01-24
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282054, "Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07282054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*